Warning: Your browser doesn't support all of the features in this Web site. Please view our accessibility page for more details.

Quick Search [?]WHAT IS THIS?
Searches this and other areas of the Web site as you type. Results appear on this page.
Also searches the entire Web site (with results on a new page) if you press enter or click on 'Go'.

Principal Investigator Profile

Prof. Frank Giles

Professor Giles has recently commenced his post as Director of the HRB Clinical Research Facility Galway. He holds joint positions in GUH, Trinity College Dublin and St James Hospital Dublin. He also has a leadership position in the HRB Wellcome Trust Dublin CRF. He is a cancer specialist with more than two decades of experience in the development of novel drugs, immunotherapies, and other highly targeted approaches, including cancer-directed viruses. He has served as principal investigator on numerous international Phase I, II and III clinical studies of many novel agents. He holds numerous patents and technology licenses. His awards have included the BioLink USA-Ireland Lifescience Award and the Medtronic Award for Health Care and Medical Science, NUIG.

Professor Giles has focused his clinical and research efforts on providing therapy for patients suffering from treatment-resistant or refractory cancer. He has pioneered the use of many agents that are now in regular use as targeted therapies for patients with cancer. In 2007, Nilotinib, a novel Bcr-Abl inhibitor, was approved in Europe and the USA for patients with chronic myeloid leukaemia, and became the latest agent for which Giles has led both the pre-clinical and clinical development. The principles of early-phase trials in oncology are readily applied to other clinical areas, including device-evaluation. He has extensive global regulatory and reimbursement strategy development and application experience.

Professor Giles is the founder and chairman of the International Oncology Study Group; a cooperative research group created in 1993 and composed of oncologists from 90 institutions in Australasia, Europe, the Middle East and the USA. He is also the founder and chairman of the Developmental Therapeutics Consortium, an international early phase study group.

His prior posts include Professor of Medicine and Chief of the Section of Developmental Therapeutics in the Department of Leukemia at the MD Anderson Cancer Center, where he also served as Vice-Chairman of the Institutional Review Board and Co-Chairman of the Division of Cancer Medicine Phase I Group. Previously, Prof. Giles also was a faculty member at the University of North Carolina at Chapel Hill and the University of California, Los Angeles. He has authored over 500 peer-reviewed articles on research in oncology in leading academic journals.

This year Professor Giles was awarded the Annual Saint Luke’s Silver Award by the Royal Academy of Medicine in Ireland, the highest honour bestowed by the Academy.

List of Recent Publications:

Giles FJ, Rosti G, Photis Beris, Richard E. Clark, Philipp le Coutre, Francois-Xavier Mahon, Juan-Luis Steegmann, Peter Valent, Saglio G. Nilotinib is superior to imatinib as first line therapy of chronic myeloid leukemia (CML): the ENESTnd study as a landmark on the path to cure in CML. Expert Review Hematology 2010

Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh CH, O'Brien S, Giles F, Bruey JM, Albitar M. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms. Public Library of Science One 5; e12165, 2010

Prajapati SI, Kilcoyne A, Samano AK, Green DP, McCarthy SD, Blackman BA, Brady MM, Zarzabal LA, Tatiparthy AK, Sledz TJ, Duong T, Ohshima-Hosoyama S, Giles FJ, Michalek JE, Rubin BP, Keller C. MicroCT-based virtual histology evaluation of preclinical medulloblastoma. Molecular Imaging Biology. 2010

Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase II study of romiplostim in patients with low- or Intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010

Mita M, Ricart A, Mita A, Romero O, Tolcher A, Desai P, Hook L, Zang E, Okereke C, Kelly K, Giles F, Rowinsky E, Takimoto C. Phase I study of E7820, an oral inhibitor of integrin α2 expression, with antiangiogenic properties, in patients with advanced malignancies. Clinical Cancer Research 2010

Bansal H, Bansal S, Rao M, Ying W, Sang J, Kelly K, Swords RP, Foley KP, Barsoum J, Repasky E, Giles FJ, Lee KP, Padmanabhan S. Heat Shock Protein 90 regulates the expression of Wilm's tumor 1 protein in myeloid leukemias. Blood 2010

K Kelly, R Swords, D Mahalingam, F Giles. Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents. Leukemia Lymphoma 2010

Fisher T, Stone RM, DeAngelo D, Galinsky I, Estey E, Cohen P, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Wong YF, Massimini G, Giles F. A Phase IIB trial of the putative FLT3 and mutlitargeted kinase inhibitor PKC412 (N-benzoylstaurosporine; Midostaurin) in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Journal of Clinical Oncology 2010

Giles FJ. Treating imatinib resistance in the few in CML - A key step towards cure in all. Leukemia Research 2010

Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GLS, Jagasia, M, Mendrek W, Fischer T, Facon T, Dünzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani, M, Cortes, J, Kantarjian, HM. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010

Swords RT, Kelly KR, Cohen SC, Miller LJ, Philbeck TE, Hacker SO, Spadaccini CJ, Giles FJ, Brenner AJ. Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficiently. Journal of Clinical Pathology 2010

Abdool A, Yeh CH, Kantarjian H, O'Brien S, Bruey JM, Giles F, Albitar M. Circulating CD33 and its clinical value in acute leukemia. Experimental Hematology 38; 462-471, 2010

Lee TS, Ma W, Zhang X, Albitar M, Giles F, Cortes J, Kantarjian H. BCR-BL1INS35 Is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response. Molecular Cancer Therapeutics.

Vey N, Giles F. Laromustine (Cloretazine). Expert Opinion Pharmacotherapy 11; 657-667, 2010

Burke A, Swords R, Kelly R, Giles F. Elacytarabine. Drugs of the Future. 2010

Sankhala KK, Pandya DM, Sarantopoulos J, Soefje SA, Giles FJ, Chawla SP. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opinion Drug Metabolism Toxicology 12; 1607-1614, 2009

Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, Bruzzi JF. Clinical utility of PET/CT in lymphoma. American Journal Roentgenology 194; 91-103, 2010

Abdel-Karim I, Plunkett WK Jr, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HM A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Investigational New Drugs 2010

HRB Clinical Research Facility Galway, National University of Ireland, Galway,
Geata an Eolais,University Road, Galway, Ireland.
Phone: +353 (0) 91 524411, Ext: 5964; Direct +353 (0) 91 495964; Fax: +353 (0) 91 585852
Email: crfg

nuigalway.ie
This page was last updated Wednesday, February 29, 2012